Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions-Reference-Cited by-同舟云学术

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

Published:2017-05-31 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Sucker Antje,Zhao Fang,Pieper Natalia,Heeke Christina,Maltaner Raffaela,Stadtler Nadine,Real Birgit,Bielefeld Nicola,Howe Sebastian,Weide Benjamin,Gutzmer Ralf,Utikal Jochen,Loquai Carmen,Gogas Helen,Klein-Hitpass Ludger,Zeschnigk Michael,Westendorf Astrid M.,Trilling Mirko,Horn Susanne,Schilling Bastian,Schadendorf Dirk,Griewank Klaus G.,Paschen Annette

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms15440.pdf

Reference61 articles.

1. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).

2. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014).

3. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

4. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

5. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies;Cancer Communications;2024-07-28

2. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07

3. SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity;Frontiers in Immunology;2024-06-14

4. DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers;eLife;2024-06-03

5. Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface density;Molecular Oncology;2024-05-28